CG Oncology, Inc. (NASDAQ:CGON) Receives $81.73 Consensus PT from Analysts

CG Oncology, Inc. (NASDAQ:CGON) has received an average rating of “Moderate Buy” from the fourteen research firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $81.7273.

Several analysts have recently issued reports on the stock. Truist Financial reissued a “buy” rating and set a $82.00 price target (up from $77.00) on shares of CG Oncology in a research report on Thursday, May 14th. Wedbush upped their target price on shares of CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Wolfe Research initiated coverage on shares of CG Oncology in a report on Tuesday, May 19th. They set a “peer perform” rating on the stock. JPMorgan Chase & Co. raised their price target on shares of CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Finally, Royal Bank Of Canada raised their price target on shares of CG Oncology from $79.00 to $81.00 and gave the company an “outperform” rating in a research report on Monday, May 11th.

Insider Buying and Selling

In related news, Director Brian Guan-Chyun Liu purchased 371,085 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were bought at an average price of $66.87 per share, for a total transaction of $24,814,453.95. Following the acquisition, the director directly owned 1,886,236 shares in the company, valued at $126,132,601.32. This trade represents a 24.49% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director James Mulay sold 24,165 shares of the stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $75.16, for a total value of $1,816,241.40. Following the completion of the sale, the director directly owned 24,165 shares in the company, valued at $1,816,241.40. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 37,129 shares of company stock valued at $2,663,817 in the last three months. 4.80% of the stock is owned by corporate insiders.

Institutional Trading of CG Oncology

Institutional investors and hedge funds have recently made changes to their positions in the company. NFSG Corp acquired a new position in CG Oncology during the first quarter worth approximately $34,000. Comerica Bank boosted its holdings in shares of CG Oncology by 100.4% in the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after acquiring an additional 515 shares during the period. LPL Financial LLC grew its position in shares of CG Oncology by 9.8% during the fourth quarter. LPL Financial LLC now owns 6,201 shares of the company’s stock worth $257,000 after acquiring an additional 551 shares during the last quarter. Whittier Trust Co. of Nevada Inc. purchased a new position in shares of CG Oncology during the fourth quarter worth approximately $27,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of CG Oncology by 33.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company’s stock valued at $163,000 after acquiring an additional 972 shares during the period. 26.56% of the stock is owned by hedge funds and other institutional investors.

CG Oncology Trading Up 5.7%

Shares of NASDAQ CGON opened at $73.03 on Tuesday. CG Oncology has a twelve month low of $23.65 and a twelve month high of $77.00. The stock has a fifty day simple moving average of $65.92 and a 200-day simple moving average of $63.24. The stock has a market capitalization of $6.44 billion, a PE ratio of -31.34 and a beta of 0.22.

CG Oncology (NASDAQ:CGON) last posted its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The company had revenue of $1.08 million during the quarter, compared to analysts’ expectations of $0.45 million. On average, equities analysts predict that CG Oncology will post -2.89 earnings per share for the current year.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.